Symptomatic diverticular disease has a high prevalence in countries with a western lifestyle. Besides antibiotics for acute diverticulitis there are no established medical interventions to prevent or to treat symptomatic diverticular disease. Due to its broad spectrum of anti-inflammatory activities, mesalazine is a candidate for the treatment of symptomatic diverticular disease. A review of the literature shows that randomized open studies using various treatment designs suggest a protective role of mesalazine in preventing recurrences of diverticulitis. Currently, 5 randomized placebo-controlled trials are active which will clarify the role of mesalazine to prevent recurrence of diverticulitis in the near future. Several randomized uncontrolled studies suggest that mesalazine improves symptoms in patients with symptomatic uncomplicated diverticular disease. The analysis of secondary end points from two randomized placebo-controlled trials suggests that mesalazine improves symptoms in diverticular disease although both studies failed to show a statistically significant advantage for mesalazine for the primary study end point. In segmental colitis associated with diverticulosis no prospective systematic studies are available. However, several case reports show a high efficacy of mesalazine in segmental colitis associated with diverticulosis.

Keywords:
Aminosalicylates, Mesalazine, Diverticulitis, Symptomatic uncomplicated diverticular disease, Segmental colitis associated with diverticulosis
1.
Parks TG: Natural history of diverticular disease of the colon. Clin Gastroenterol 1975;4:53–69.
2.
Stollman N, Raskin JB: Diverticular disease of the colon. Lancet 2004;363:631–639.
3.
Floch CL: Diagnosis and management of acute diverticulitis. J Clin Gastroenterol 2006;40:S136–S144.
4.
Gatta L, Vakil N, Vaira D, Pilotto A, Curlo M, Comparato G, Leandro G, Ferro U, Lera M, Milletti S, Di Mario F: Efficacy of 5-ASA in the treatment of colonic diverticular disease. J Clin Gastroenterol 2010;44:113–119.
5.
Lenza C, Das KM: Mesalamine in the treatment of diverticular disease. J Clin Gastroenterol 2011;45:S53–S61.
6.
Ligumsky M, Karmeli F, Sharon P, Zor U, Cohen F, Rachmilewitz D: Enhanced thromboxane A2 and prostacyclin production by cultured rectal mucosa in ulcerative colitis and its inhibition by steroids and sulfasalazine. Gastroenterology 1981;81:444–449.
7.
Sharon P, Ligumsky M, Rachmilewitz D, Zor U: Role of prostaglandins in ulcerative colitis-enhanced production during active disease and inhibition by sulfasalazine. Gastroenterology 1978;75:638–640.
8.
Keating JJ, Maxwell WJ, Hogan FP, Keeling PWN: Effects of prednisolone, sulphasalazine, 5-aminosalicylic acid and indomethacin on prostaglandin E2 and leucotrine B4 production. Jubilee Meeting of the British Society of Gastroenterology, London, 1987, abstr. Th79.
9.
Greenfield SM, Boswell DJ, Punchard NA, Thompson RPH: The effects of 5-aminosalicylic acid and acetyl-5-aminosalicylic acid on lipid peroxidation in erythrocytes and prostaglandin production by mononuclear cells. Aliment Pharmacol Ther 1992;6:671–683.
10.
Lauritsen K, Laursen LS, Bukhave K, Rask-Madsen J: Effect of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis. Gastroenterology 1986;91:837–844.
11.
Nielsen OH, Bukhave K, Elmgreen J, Ahnfeldt-Rønne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci 1987;32:577–582.
12.
Peskar BM, Dreyling KW, May B, Schaarschmidt K, Goebell H: Possible mode of action of 5-aminosalicylic acid. Dig Dis Sci 1987;32(suppl):S51–S56.
13.
Rachmilewitz D, Eliakim R, Simon P, Ligumsky M, Karmeli F: Role of cytokines and platelet activating factor in the pathogenesis of inflammatory bowel disease; in Goebell H, Malchow H, Ewe K, Koelbel C (eds): Inflammatory Bowel Disease – Progress in Basic Research and Clinical Implications. Dordrecht, Kluwer, 1991, pp 153–159.
14.
Mahida YR, Lamming CED, Gallagher A, Hawthorne AB, Hawkey CJ: 5-Aminosalicylic acid is a potent inhibitor of interleukin-1beta production in organ culture of colonic biopsy specimens from patients with inflammatory bowel disease. Gut 1991;32:50–54.
15.
Rachmilewitz D, Karmeli F, Schwartz LW, Simon PL: Effect of aminophenols (5-ASA and 4-ASA) on colonic interleukin-1 generation. Gut 1992;33:929–932.
16.
Greenfield SM, Hamblin AS, Shakoor ZS, Teare JP, Punchard NA, Thompson RPH: Inhibition of leucocyte adhesion molecule upregulation by tumor necrosis factor α: a novel mechanism of action of sulphasalazine. Gut 1993;34:252–256.
17.
Molin L, Stendahl O: The effect of sulfasalazine and its active components on human polymorphonuclear leukocyte function in relation to ulcerative colitis. Acta Med Scand 1979;206:451–457.
18.
Rhodes JM, Bartholomew TC, Jewell DP: Inhibition of leucocyte motility by drugs used in ulcerative colitis. Gut 1981;22:642–647.
19.
Wandall JH: Effects of sulphasalazine and its metabolites on neutrophil chemotaxis, superoxide production, degranulation and translocation of cytochrome b-245. Aliment Pharmacol Ther 1991;5:609–619.
20.
Nikolaus S, Fölsch UR, Schreiber S: Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology 2000;47:71–82.
21.
Burress GC, Musch MW, Jurivich DA, Welk J, Chang EB: Effects of mesalamine on the hsp72 stress response in rat IEC-18 intestinal epithelial cells. Gastroenterology 1997;113:1474–1479.
22.
Shanahan F, Niederlehner A, Carramanzana N, Anton P: Sulfasalazine inhibits the binding of TNF alpha to its receptor. Immunopharmacology 1990;20:217–224.
23.
Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Anwerx J, Metzger D, Wahli W, Desvergne B, Naccari GL, Chavatte P, Farce A, Bulois P, Cortot A, Colombel JF, Desreumaux P: Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-γ. J Exp Med 2005;201:1205–1215.
24.
Allgayer H, Höfer P, Schmidt M, Böhne P, Kruis W, Gugler R: Superoxide hydroxyl and fatty acid radical scavenging by aminosalicylates – direct evaluation with electron spin resonance spectroscopy. Biochem Pharmacol 1992;43:259–262.
25.
Gionchetti P, Guarnieri C, Campieri M, Belluzzi A, Brignola C, Iannone P, Miglioli M, Barbara L: Scavenger effect of sulfasalazine, 5-aminosalicylic acid, and olsalazine on superoxide radical generation. Dig Dis Sci 1991;36:174–178.
26.
Miyachi Y, Yoshioka A, Imamura S, Niwa Y: Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut 1987;28:190–195.
27.
Hansen O, Stock W: Prophylaktische Operation bei der Divertikelkrankheit des Kolons – Stufenkonzept durch exakte Stadieneinteilung. Langenbecks Arch Chir 1999 (suppl II):1257–1260.
28.
Broderick-Villa G, Burchette RJ, Collins JC, Abbas MA, Haigh PI: Hospitalization for acute diverticulitis does not mandate routine elective colectomy. Arch Surg 2005;140:576–581.
29.
Mueller MH, Glatzle J, Kasparek MS, Becker HD, Jehle EC, Zittel TT, Kreis ME: Long-term outcome of conservative treatment in patients with diverticulitis of the sigmoid colon. Eur J Gastroenterol Hepatol 2005;17:649–654.
30.
Trespi E, Colla C, Panizza P, Polino MG, Venturini A, Bottani G, De Vecchi P, Matti C: Therapeutic and prophylactic role of mesalazine (5-ASA) in symptomatic diverticular disease of the colon. Min Gastroenterol Dietol 1999;45:245–252.
31.
Tursi A, Brandimarte G, Daffina R: Long-term treatment with mesalazine and rifaximin versus rifaximin alone for patients with recurrent attacks of acute diverticulitis of colon. Digest Liver Dis 2002;34:510–515.
32.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W, Aiello F: Balsalazide and/or high-potency probiotic mixture (VSL#3) in maintaining remission after attack of acute, uncomplicated diverticulitis of the colon. Int J Colorectal Dis 2007;22:1103–1108.
33.
Dr. Falk Pharma GmbH: Mesalazine granules versus placebo for the prevention of recurrence of diverticulitis; in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http://clinicaltrials.gov/ct2/show/NCT00695643.
34.
Dr. Falk Pharma GmbH: Two doses mesalazine granules versus placebo for the prevention of recurrence of diverticulitis; in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http://clinicaltrials.gov/ct2/show/NCT01038739.
35.
Shire Pharmaceutical Development, Whitaker T: Prevention of recurrence of diverticulitis (PREVENT 1); in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http://clinicaltrials.gov/ct2/show/NCT00545740.
36.
Shire Pharmaceutical Development, Whitaker T: Prevention of recurrence of diverticulitis (PREVENT 2); in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http://clinicaltrials.gov/ct2/show/NCT00545103.
37.
Comparato G, Fanigliulo L, Cavallaro LG, Aragona G, Cavestro GM, Iori V, Maino M, Mazzocchi G, Muzzetto P, Colla G, Sianesi M, Franzé A, Di Mario F: Prevention of complications and symptomatic recurrence in diverticular disease with mesalazine: a 12-month follow-up. Dig Dis Sci 2007;52:2934–2941.
38.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Continuous versus cyclic mesalazine therapy for patients affected by recurrent symptomatic uncomplicated diverticular disease of the colon. Dig Dis Sci 2007;52: 671–674.
39.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Mesalazine and/or Lactobacillus casei in preventing recurrence of symptomatic uncomplicated diverticular disease of the colon. A prospective, randomized, open-label study. J Clin Gastroenterol 2006;40:312–316.
40.
Tursi A, Brandimarte G, Giorgetti GM, Elisei W: Mesalazine and/or Lactobacillus casei in maintaining long-term remission of symptomatic uncomplicated diverticular disease of the colon. Hepatogastroenterology 2008;55:916–920.
41.
Kruis W, Meier E, Schumacher M, Mickisch O, Schneider W, Greinwald R, Müller R: Treatment of painful diverticular disease of the colon with mesalamine: a placebo-controlled study. Gastroenterology 2007;132:A-191.
42.
Stollman N, Magowan S, Shanahan F, Quigley E: Efficacy of delayed-release mesalamine in the prevention of GI symptoms following acute diverticulitis: results of the DIVA trial. Am J Gastroenterology 2010;105(suppl 1):S139.
43.
University of Nottingham, Cartledge P: Mechanistic randomized controlled trial (RCT) of mesalazine in symptomatic diverticular disease; in: ClinicalTrials.gov [Internet]. Bethesda, National Library of Medicine, 2000 [cited 2010 Sep 12]. http://clinicaltrials.gov/ct2/show/NCT00663247.
44.
Imperiali G, Meucci G, Alvisi C, Fasoli R, Ferrara A, Girelli CM, Rocca F, Saibeni S, Minoli G, Gruppo di Studio per le Malattie Infiammatorie Intestinali (GSMII). Segmental colitis associated with diverticula: a prospective study. Am J Gastroenterol 2000;95:1014–1016.
45.
Mulhall AM, Mahid SS, Petras RE, Galandiuk S: Diverticular disease associated with inflammatory bowel disease-like colitis: a systematic review. Dis Colon Rectum 2009;52:1072–1079.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.